Omalizumab

• Allergic Asthma
• Chronic Spontaneous Urticaria
• Chronic Rhinosinusitis with Nasal Polyps

Omalizumab (Xolair) is a humanized monoclonal antibody that binds free immunoglobulin E (IgE) and lowers allergic activation. It is used as add-on therapy for moderate-to-severe persistent allergic asthma inadequately controlled with inhaled corticosteroids, for chronic spontaneous urticaria that remains symptomatic despite antihistamines, for chronic rhinosinusitis with nasal polyps, and most recently for IgE-mediated food allergy in patients aged 1 year and older to reduce the risk of allergic reactions to accidental exposure. As the first FDA-approved anti-IgE biologic, it transformed care for patients with severe allergic disease and is administered by allergy and immunology specialists.

Mechanism of Action

IgE is the central antibody in immediate hypersensitivity reactions. When an allergen cross-links IgE bound to high-affinity FcεRI receptors on mast cells and basophils, those cells degranulate and release histamine, leukotrienes, prostaglandins, and tryptase, producing the cascade responsible for asthma, urticaria, and anaphylaxis. Omalizumab binds the C epsilon 3 region of free IgE in serum and interstitial fluid, blocking it from attaching to FcεRI in the first place. Because IgE bound to receptors is not affected directly, the clinical effect develops over weeks as receptor-bound IgE turns over and surface FcεRI expression downregulates.

This downregulation is one of the most important secondary effects of treatment. Within months, FcεRI density on basophils can drop more than 95 percent, and mast cell expression follows more slowly. The net result is fewer cells primed to release mediators, blunted early- and late-phase allergic responses, and a substantially raised threshold for clinical reactions. Omalizumab does not interact with the cytochrome P450 system and is cleared by the reticuloendothelial system, so traditional small-molecule drug interactions do not apply. The American Academy of Allergy, Asthma and Immunology and the National Institutes of Health recognize anti-IgE therapy as standard of care for selected patients with severe allergic disease.

Clinical Use

For allergic asthma, omalizumab is reserved for patients aged 6 and older with positive skin or in vitro reactivity to a perennial aeroallergen and persistent symptoms despite high-dose inhaled corticosteroids combined with a long-acting beta-agonist. Total IgE level and body weight must fall within the dosing tables. For chronic spontaneous urticaria, omalizumab is approved in adolescents and adults still symptomatic on H1 antihistamines at up to four times the standard dose, and dosing does not depend on IgE level. For nasal polyps, it is added to intranasal corticosteroids for adults with inadequate control. The food allergy indication is the newest, supporting reduction of allergic reaction risk in patients with confirmed IgE-mediated food allergy who continue strict allergen avoidance.

Alternatives include other biologics such as mepolizumab, reslizumab, benralizumab, dupilumab, and tezepelumab for severe asthma, with selection guided by phenotype. For chronic urticaria, dupilumab and remibrutinib are emerging options. For nasal polyps, dupilumab competes head-to-head with omalizumab. Patient selection requires confirmation of allergic mechanism, attention to baseline IgE and weight, and documented inadequate control on optimized standard therapy. Our overview of navigating allergy season reviews the broader allergic disease spectrum.

How to Take It

Omalizumab is given by subcutaneous injection. Doses range from 75 to 600 mg, divided across one to three injection sites, typically every two or four weeks based on the indication, baseline serum total IgE, and body weight. The first three doses are usually administered in a healthcare setting because of the risk of anaphylaxis; selected stable patients can later self-inject at home with the prefilled syringe or autoinjector after thorough training. Injections are placed in the upper arm, thigh, or abdomen, with site rotation. Patients should remain near medical care for an observation period after early doses, longer for the first injection, then shorter as tolerance is established.

A missed dose should be administered as soon as possible. Patients prescribed for asthma should continue their inhaled corticosteroid and other controller therapy; abrupt withdrawal of controllers is dangerous. Refrigerated storage is required, and the syringe should be allowed to reach room temperature for 15 to 30 minutes before injection to reduce sting. During the first weeks patients may notice injection site soreness, mild headache, or upper respiratory complaints. Clinical improvement in asthma and urticaria typically becomes apparent over 12 to 16 weeks; food allergy benefit is judged by oral food challenge after several months of dosing.

Monitoring and Follow-Up

Baseline labs include total serum IgE, complete blood count with differential, and weight. Asthma assessment includes spirometry and Asthma Control Test or ACQ-6. Chronic urticaria requires a baseline UAS7 or UCT score, and nasal polyps benefit from a SNOT-22 questionnaire. Once therapy begins, total IgE will appear elevated because the assay measures both free and antibody-bound IgE; this is expected and not a marker of failure. Symptom and exacerbation monitoring at three and six months is more informative than IgE levels.

Clinically meaningful response includes reduced exacerbations, improved FEV1, lower oral steroid requirement in asthma, improvement of UAS7 by at least 11 points or remission in urticaria, and reduced polyp size or symptom score. If no response after 16 weeks, treatment should be reassessed. Long-term safety monitoring focuses on hypersensitivity reactions, including delayed anaphylaxis up to 24 hours after dosing. All patients should be prescribed an epinephrine autoinjector and trained in its use. Red numbers include any anaphylaxis sign, severe injection-site reaction, persistent fever, lymphadenopathy, or new neurologic symptoms.

Special Populations

Elderly patients tolerate omalizumab similarly to younger adults; dose is determined by weight and IgE level, not age. Renal and hepatic impairment do not require dose adjustment because clearance is independent of these organs. Pediatric safety is established for asthma at 6 years, urticaria at 12, and food allergy at 1 year. Pregnancy data from the EXPECT registry have not shown an increased risk of major malformations, and uncontrolled severe asthma carries clear maternal and fetal risk; therapy is often continued after individualized counseling. Omalizumab is a large IgG molecule unlikely to be absorbed orally, so breastfeeding while on therapy is generally considered acceptable. Patients with active helminth infection should be treated before initiation; geographic risk should be screened in those with relevant travel history. Patients should not start omalizumab during an acute exacerbation. The Centers for Disease Control and Prevention emphasizes that biologic patients should remain current on inactivated vaccines and avoid live vaccines while immunomodulated.

When to Contact Your Doctor

Seek emergency care immediately for hives, throat tightness, wheezing, lightheadedness, or fainting after an injection, even if these occur 12 to 24 hours later. Persistent fever, joint pain, or rash several days after an injection may indicate serum sickness-like reaction and should be evaluated. Worsening asthma symptoms, urticaria flare, increased rescue inhaler use, or any need for emergency or hospital care should trigger early follow-up. New unexplained pulmonary symptoms with eosinophilia or vasculitis are rare but reported and require evaluation. Patients planning pregnancy or with a new pregnancy should discuss continuation versus alternatives with their physician.

For families managing food allergy in children, omalizumab is not a replacement for strict allergen avoidance or for an emergency action plan. Patients and caregivers must continue to read food labels carefully, communicate allergies in restaurants and schools, and carry epinephrine. The benefit of omalizumab in this setting is to raise the threshold dose required to trigger a reaction during accidental exposure, which provides meaningful safety margin but does not equate to cure. For chronic urticaria patients, antihistamine therapy at standard or up-titrated doses is generally continued during omalizumab treatment for several months, then carefully tapered if remission is achieved. For asthma patients, biologic therapy works alongside trigger reduction strategies including controlling indoor allergens, addressing dust mites and mold in our humid climate, treating allergic rhinitis aggressively, and avoiding tobacco smoke exposure. Our office can help coordinate the multidisciplinary care that severe allergic disease often requires.

If severe allergic disease is limiting your daily life despite standard therapy, our internal medicine team can help coordinate the workup and refer for biologic consideration. Contact us or schedule a visit to discuss whether anti-IgE therapy fits your plan.